Induction of apoptotic cell death by phytoestrogens by up-regulating the levels of phospho-p53 and p21 in normal and malignant estrogen receptor α-negative breast cells

Nutrition Research

Volumn 31, Issue 2, 2011, Pages 139-146

  Seo, Hye Sook ^a   Ju, Ji hyun ^a   Jang, Kibeom ^a   Shin, Incheol ^a  

^a Hanyang University   (South Korea)

Author keywords

Breast cancer; MCF 10A; MDA MB 231; P21; P53; Phytoestrogens

Indexed keywords

APIGENIN; CELL CYCLE PROTEIN; CELL DIVISION CONTROL PROTEIN 2 HOMOLOG; CYCLIN B1; CYCLIN D1; ESTROGEN RECEPTOR ALPHA; GENISTEIN; PHOSPHATASE; PHOSPHO CELL DIVISION CONTROL PROTEIN 2 HOMOLOG; PHYTOESTROGEN; PROTEIN BCL XL; PROTEIN P21; PROTEIN P27; PROTEIN P53; QUERCETIN; TENSIN; UNCLASSIFIED DRUG;

ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CELL; CANCER INHIBITION; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL POPULATION; CELL PROLIFERATION; CONTROLLED STUDY; GENE TARGETING; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; UPREGULATION; WESTERN BLOTTING;

APIGENIN; APOPTOSIS; BREAST; BREAST NEOPLASMS; CELL DIVISION; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P21; ESTROGEN RECEPTOR ALPHA; FEMALE; G2 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENISTEIN; HUMANS; PHYTOESTROGENS; QUERCETIN; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 79952681368     PISSN: 02715317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nutres.2011.01.011     Document Type: Article

References (33)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010, 60:277-300.
2. Rochefort H., Glondu M., Sahla M.E., Platet N., Garcia M. How to target estrogen receptor-negative breast cancer?. Endocr Relat Cancer 2003, 10:261-266.
3. Sirtori C.R., Arnoldi A., Johnson S.K. Phytoestrogens: end of a tale?. Ann Med 2005, 37:423-438.
4. Mense S.M., Hei T.K., Ganju R.K., Bhat H.K. Phytoestrogens and breast cancer prevention: possible mechanisms of action. Environ Health Perspect 2008, 116:426-433.
5. Velentzis L.S., Woodside J.V., Cantwell M.M., Leathem A.J., Keshtgar M.R. Do phytoestrogens reduce the risk of breast cancer and breast cancer recurrence? What clinicians need to know. Eur J Cancer 2008, 44:1799-1806.
6. Duffy C., Perez K., Partridge A. Implications of phytoestrogen intake for breast cancer. CA Cancer J Clin 2007, 57:260-277.
7. Duffy C., Cyr M. Phytoestrogens: potential benefits and implications for breast cancer survivors. J Womens Health (Larchmt) 2003, 12:617-631.
8. Murkies A.L., Wilcox G., Davis S.R. Clinical review 92: phytoestrogens. J Clin Endocrinol Metab 1998, 83:297-303.
9. Tham D.M., Gardner C.D., Haskell W.L. Clinical review 97: potential health benefits of dietary phytoestrogens: a review of the clinical, epidemiological, and mechanistic evidence. J Clin Endocrinol Metab 1998, 83:2223-2235.
10. Limer J.L., Speirs V. Phyto-oestrogens and breast cancer chemoprevention. Breast Cancer Res 2004, 6:119-127.
11. Seo H.S., DeNardo D.G., Jacquot Y., Laios I., Vidal D.S., Zambrana C.R., et al. Stimulatory effect of genistein and apigenin on the growth of breast cancer cells correlates with their ability to activate ER alpha. Breast Cancer Res Treat 2006, 99:121-134.
12. Choi E.J., Kim G.H. Apigenin causes G(2)/M arrest associated with the modulation of p21(Cip1) and Cdc2 and activates p53-dependent apoptosis pathway in human breast cancer SK-BR-3 cells. J Nutr Biochem 2009, 20:285-290.
13. Wang W., Heideman L., Chung C.S., Pelling J.C., Koehler K.J., Birt D.F. Cell-cycle arrest at G2/M and growth inhibition by apigenin in human colon carcinoma cell lines. Mol Carcinog 2000, 28:102-110.
14. Choi Y.H., Lee W.H., Park K.Y., Zhang L. p53-Independent induction of p21 (WAF1/CIP1), reduction of cyclin B1 and G2/M arrest by the isoflavone genistein in human prostate carcinoma cells. Jpn J Cancer Res 2000, 91:164-173.
15. Upadhyay S., Neburi M., Chinni S.R., Alhasan S., Miller F., Sarkar F.H. Differential sensitivity of normal and malignant breast epithelial cells to genistein is partly mediated by p21 (WAF1). Clin Cancer Res 2001, 7:1782-1789.
16. Shen Y., White E. p53-Dependent apoptosis pathways. Adv Cancer Res 2001, 82:55-84.
17. Schuler M., Green D.R. Mechanisms of p53-dependent apoptosis. Biochem Soc Trans 2001, 29:684-688.
18. Stiewe T., Putzer B.M. Role of the p53-homologue p73 in E2F1-induced apoptosis. Nat Genet 2000, 26:464-469.
19. Goldstein I., Marcel V., Olivier M., Oren M., Rotter V., Hainaut P. Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies. Cancer Gene Ther 2011, 18:2-11.
20. Werner H., Karnieli E., Rauscher F.J., Leroith D. Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. Proc Natl Acad Sci U S A 1996, 93:8318-8323.
21. Gartel A.L., Tyner A.L. The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 2002, 1:639-649.
22. Sulaimon S.S., Kitchell B.E. The basic biology of malignant melanoma: molecular mechanisms of disease progression and comparative aspects. J Vet Intern Med 2003, 17:760-772.
23. Deng C., Zhang P., Harper J.W., Elledge S.J., Leder P. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 1995, 82:675-684.
24. Niculescu A.B., Chen X., Smeets M., Hengst L., Prives C., Reed S.I. Effects of p21(Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Mol Cell Biol 1998, 18:629-643.
25. Ogryzko V.V., Wong P., Howard B.H. WAF1 retards S-phase progression primarily by inhibition of cyclin-dependent kinases. Mol Cell Biol 1997, 17:4877-4882.
26. Gartel A.L., Tyner A.L. Transcriptional regulation of the p21((WAF1/CIP1)) gene. Exp Cell Res 1999, 246:280-289.
27. el-Deiry W.S., Tokino T., Waldman T., Oliner J.D., Velculescu V.E., Burrell M., Hill D.E., Healy E., Rees J.L., Hamilton S.R., et al. Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res 1995, 55:2910-2919.
28. Hikita H., Takehara T., Shimizu S., Kodama T., Li W., Miyagi T., et al. Mcl-1 and Bcl-xL cooperatively maintain integrity of hepatocytes in developing and adult murine liver. Hepatology 2009, 50:1217-1226.
29. Castilla C., Congregado B., Chinchon D., Torrubia F.J., Japon M.A., Saez C. Bcl-xL is overexpressed in hormone-resistant prostate cancer and promotes survival of LNCaP cells via interaction with proapoptotic Bak. Endocrinology 2006, 147:4960-4967.
30. Yuan J., Yan R., Kramer A., Eckerdt F., Roller M., Kaufmann M., et al. Cyclin B1 depletion inhibits proliferation and induces apoptosis in human tumor cells. Oncogene 2004, 23:5843-5852.
31. Kawamoto H., Koizumi H., Uchikoshi T. Expression of the G2-M checkpoint regulators cyclin B1 and cdc2 in nonmalignant and malignant human breast lesions: immunocytochemical and quantitative image analyses. Am J Pathol 1997, 150:15-23.
32. Soria J.C., Jang S.J., Khuri F.R., Hassan K., Liu D., Hong W.K., et al. Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication. Cancer Res 2000, 60:4000-4004.
33. Hassan K.A., Ang K.K., El-Naggar A.K., Story M.D., Lee J.I., Liu D., et al. Cyclin B1 overexpression and resistance to radiotherapy in head and neck squamous cell carcinoma. Cancer Res 2002, 62:6414-6417.